nach oben

Clinical and Translational Oncology

Erschienen in:

01.11.2015 | Correspondence

GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment

verfasst von: P. J. Vlachostergios, R. L. Balmiki, R. Daya

Erschienen in: Clinical and Translational Oncology | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Excerpt

We read with great interest the study of Mandelin et al. which constitutes a substantial breakthrough in the exploitation of phage display technology for investigation of a unique osteoblastic prostate castrate-resistant cancer model [1]. More importantly, the two peptides identified in this study, PKRGFQD and SNTRVAP, together with their respective receptors, α2-macroglobulin, and glucose-regulated protein 78 (GRP78) were found to be enriched in the tumors and are suggested as potentially drug able targets for metastatic androgen-independent prostate cancer (PC) [1]. …

Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, et al. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci USA. 2015. (pii: 201500128).

Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, et al. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate. 2013;73:932–40.PubMedCentralCrossRefPubMed

Asplin IR, Wu SM, Mathew S, Bhattacharjee G, Pizzo SV. Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis. Blood. 2001;97:3450–7.CrossRefPubMed

Booth L, Roberts JL, Tavallai M, Nourbakhsh A, Chuckalovcak J, Carter J, et al. OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood Brain Barrier: Implications for Anti-Cancer Therapies. J Cell Physiol. 2015. doi:10.1002/jcp.24977.

Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014;6:252ra122.

Misra UK, Pizzo SV. Activated α2-Macroglobulin Binding to Human Prostate Cancer Cells Triggers Insulin-like Responses. J Biol Chem. 2015. (pii: jbc.M114.617837).

Misra UK, Pizzo SV. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells. PLoS ONE. 2012;7:e51735.PubMedCentralCrossRefPubMed

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, et al. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2015;13:113–23.CrossRefPubMed

Pootrakul L, Datar RH, Shi SR, Cai J, Hawes D, Groshen SG, et al. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res. 2006;12:5987–93.CrossRefPubMed

10.

Misra UK, Payne S, Pizzo SV. Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. J Biol Chem. 2011;286:1248–59.PubMedCentralCrossRefPubMed

11.

Tan SS, Ahmad I, Bennett HL, Singh L, Nixon C, Seywright M, et al. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J Pathol. 2011;223:81–7.CrossRefPubMed

12.

Zhang Y, Tseng CC, Tsai YL, Fu X, Schiff R, Lee AS. Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3 K and enhances PI(3,4,5)P3 production. PLoS ONE. 2013;8:e80071.PubMedCentralCrossRefPubMed

13.

Tang Y, Wang L, Goloubeva O, Khan MA, Zhang B, Hussain A. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy. Clin Cancer Res. 2008;14:2936–43.CrossRefPubMed

14.

Vasileiou C, Hatzidaki E, Karkabounas A, Maragkouli E, Vaiou M, Dimas K, et al. Effect of ET-1, FGF-2, and HGF on intracellular steroidogenesis in prostate cancer cells. J Clin Oncol. 2013;31(suppl):abstr e16083.

15.

Gonzalez-Gronow M, Cuchacovich M, Llanos C, Urzua C, Gawdi G, Pizzo SV. Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res. 2006;66:11424–31.CrossRefPubMed

16.

Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, et al. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol. 2007;38:1547–52.CrossRefPubMed

17.

Bartkowiak K, Effenberger KE, Harder S, Andreas A, Buck F, Peter-Katalinic J, et al. Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J Proteome Res. 2010;9:3158–68.CrossRefPubMed

18.

Pfaffenbach KT, Pong M, Morgan TE, Wang H, Ott K, Zhou B, et al. GRP78/BiP is a novel downstream target of IGF-1 receptor mediated signaling. J Cell Physiol. 2012;227:3803–11.PubMedCentralCrossRefPubMed

19.

Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, et al. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014;74:225–34.CrossRefPubMed

20.

Aggarwal RR, Ryan CJ, Chan JM. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urol Oncol. 2013;31:522–30.CrossRefPubMed

21.

Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, et al. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014;66:468–74.CrossRefPubMed

22.

Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN Jr, et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014;33:4521–30.PubMedCentralCrossRefPubMed

23.

Abdel Malek MA, Jagannathan S, Malek E, Sayed DM, Elgammal SA, Abd El-Azeem HG, et al. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget. 2015;6:3098–110.PubMedCentralCrossRefPubMed

24.

Leclerc GM, Leclerc GJ, Kuznetsov JN, DeSalvo J, Barredo JC. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts. PLoS ONE. 2013;8:e74420.PubMedCentralCrossRefPubMed

25.

Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012;110:1729–35.CrossRefPubMed

26.

Misra UK, Pizzo SV. Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. Cancer Biol Ther. 2010;9:142–52.CrossRefPubMed

27.

Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra SK, et al. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3 K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res. 2013;19:6802–11.PubMedCentralCrossRefPubMed

28.

Maddalo D1, Neeb A, Jehle K, Schmitz K, Muhle-Goll C, Shatkina L, et al. A peptidic unconjugated GRP78/BiP ligand modulates the unfolded protein response and induces prostate cancer cell death. PLoS One. 2012 7:e45690.

29.

Roller C, Maddalo D. The Molecular Chaperone GRP78/BiP in the Development of Chemoresistance: Mechanism and Possible Treatment. Front Pharmacol. 2013;4:10.PubMedCentralCrossRefPubMed

30.

Delie F, Petignat P, Cohen M. GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78. Target Oncol. 2013;8:225–30.CrossRefPubMed

31.

Su SF, Chang YW, Andreu-Vieyra C, Fang JY, Yang Z, Han B, et al. miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene. 2013;32:4694–701.PubMedCentralCrossRefPubMed

32.

Wu Y, Fabritius M, Ip C. Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer. Cancer Biol Ther. 2009;8:146–52.PubMedCentralCrossRefPubMed

33.

Zu S, Ma W, Xiao P, Cui Y, Ma T, Zhou C, et al. Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells. Urol Int. 2015 [Epub ahead of print].

34.

Lee E, Nichols P, Groshen S, Spicer D, Lee AS. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer. 2011;128:726–31.PubMedCentralCrossRefPubMed

Titel: GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment
verfasst von: P. J. Vlachostergios
R. L. Balmiki
R. Daya
Publikationsdatum: 01.11.2015
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 11/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1324-9

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment

Excerpt

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2015

Intraoperative electron-beam radiation therapy with or without external-beam radiotherapy in the management of paraaortic lymph-node oligometastases from gynecological malignancies

MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer

Autologous tumor lysate/Bacillus Calmette–Guérin immunotherapy as an adjuvant to conventional breast cancer therapy

The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival

Surgery combined with chemotherapy for recurrent gastric cancer achieves better long-term prognosis

Effectiveness and toxicity of helical tomotherapy for patients with locally recurrent nasopharyngeal carcinoma

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie